Venrock

Astronomer, Inc. is a company based in Cincinnati, Ohio, that specializes in developing a managed platform for data orchestration, primarily utilizing Apache Airflow. Established in 2014, Astronomer offers a comprehensive suite of products and services through its platform, known as Astro. This platform is designed to streamline the process of building, running, and monitoring data pipelines-as-code, catering to the needs of data engineers, scientists, and analysts. By providing tools for deploying, managing, and scaling data workflows, Astronomer enhances the availability of trusted data for organizations, making it easier for data teams to conduct business analytics effectively. As a commercial developer of Airflow, Astronomer plays a significant role in the data orchestration landscape, serving hundreds of thousands of teams globally.

Jade Biosciences is a biopharmaceutical company dedicated to developing innovative therapies for unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the APRIL pathway for treating IgA nephropathy, with initial clinical trials planned. Additionally, Jade has two preclinical antibody discovery programs, JADE-002 and JADE-003. The company was founded upon assets licensed from Paragon Therapeutics.

AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments.

Surrozen, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted regenerative antibodies to repair damaged tissues and improve organ function. The company utilizes antibody platforms that act as Wnt and R-spondin mimetics to stimulate tissue regeneration in a variety of organs. Its key programs include SZN-043, which aims to promote hepatocyte regeneration in liver diseases, and SZN-1326, designed to repair diseased epithelial tissue for patients with inflammatory bowel disease. Surrozen's research targets several disease areas, including conditions affecting the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system, by engaging the body’s natural biological repair mechanisms. The company was incorporated in 2015 and continues to advance its innovative therapeutic approaches.

Expedition Therapeutics operates as an unincorporated association.

Auditoria.AI, Inc., founded in 2019 and based in Santa Clara, California, specializes in providing technology-driven financial solutions for enterprise accounting and auditing. The company leverages advanced artificial intelligence and machine learning to enhance compliance and streamline finance operations. Its flagship product utilizes natural language processing and predictive analytics to automate back-office processes, minimizing friction and repetition for finance teams. By focusing on automation, Auditoria.AI aims to deliver real-time insights that empower organizations to improve efficiency and decision-making in their financial operations.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Enterprise service combining AI and data insights to increase a team's impact

GenLogs is a freight intelligence company that offers truck carrier mapping services via AI-driven roadside sensors.

Oumi is a group of academics, developers dedicated to fostering greater transparency and cooperation in frontier AI.

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes revolutionary medicines for autoimmune illnesses. The company utilizes its team's experience in drug development to secure top-tier assets focused on promising targets, and implementing them in disease areas with considerable unmet needs.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Cidara Therapeutics is a biotechnology company based in San Diego, California, established in 2012. The company specializes in the discovery and development of innovative anti-infective therapies for serious diseases, particularly those that affect individuals with compromised immune systems. Its lead candidate, rezafungin acetate, is an antifungal agent designed to treat and prevent severe invasive fungal infections, such as candidemia and invasive candidiasis, which carry significant mortality risks. In addition to its antifungal efforts, Cidara is advancing its proprietary Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating various viral infections, including influenza, RSV, HIV, and coronavirus. Cidara's mission is to transform treatment and prevention strategies for life-threatening illnesses.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines targeting verified biology to improve care for patients with solid tumors.

enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.

Suki is a technology company focused on enhancing healthcare documentation through AI-driven voice solutions. Its flagship product, Suki Assistant, allows physicians to complete administrative tasks more efficiently, significantly reducing the time spent on documentation. The company also offers a proprietary voice platform that leverages advanced natural language processing and machine learning technologies, ensuring high accuracy and a seamless user experience. By providing these innovative voice tools, Suki aims to alleviate the administrative burden on clinicians, ultimately transforming the healthcare technology landscape into a more assistive and integrated system.

Scope3 operates a supply chain emissions data platform that provides accurate and comprehensive emissions data to assist companies in integrating sustainability into their business decisions. The company develops models that outline the core inputs and outputs for products and services within the supply chain, enabling organizations to design more sustainable systems. Additionally, Scope3 prepares monthly sustainability reports that offer updated emissions data, allowing businesses to swiftly adapt to external changes and recognize their efforts in reducing carbon footprints.

Candid Therapeutics is a biotechnology company specializing in the development of innovative therapies for immunological disorders. The company's primary focus is on creating novel, user-friendly treatments for autoimmune diseases. Their core technology involves advanced T-cell engager antibodies, which precisely redirect T-cells to selectively eliminate autoreactive B-cells, aiming to deliver transformative efficacy and improved therapeutic outcomes for patients.

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Vanilla is an innovative Estate Advisory Platform designed to enhance the estate planning experience for wealth management firms and their clients. By providing a comprehensive suite of tools, Vanilla enables advisors, planners, and estate attorneys to offer tailored advice, strengthen client relationships, and attract new business. The platform addresses inefficiencies in document preparation and enhances understanding of estate complexities, making it easier for clients to navigate estate-related challenges after a death. Ultimately, Vanilla aims to simplify and scale estate analysis, allowing estate professionals to deliver more value and support to their clients in managing estate tax considerations and planning effectively.

Tenax Therapeutics, Inc. is a specialty pharmaceutical company dedicated to the identification, development, and commercialization of products aimed at addressing cardiovascular and pulmonary diseases with significant unmet medical needs. Headquartered in Morrisville, North Carolina, Tenax focuses on levosimendan, a pharmaceutical product designed to reduce morbidity and mortality in cardiac surgery patients at risk for low cardiac output syndrome. The company is also actively conducting a Phase 2 clinical trial to explore the efficacy of levosimendan in treating pulmonary hypertension associated with heart failure with preserved ejection fraction. Additionally, Tenax is involved in developing novel formulations of imatinib mesylate, a kinase inhibitor with the potential to serve as a disease-modifying therapy for pulmonary arterial hypertension. Founded in 1967, Tenax Therapeutics underscores its commitment to advancing treatments within these critical therapeutic areas.

Jade Biosciences is a biopharmaceutical company dedicated to developing innovative therapies for unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the APRIL pathway for treating IgA nephropathy, with initial clinical trials planned. Additionally, Jade has two preclinical antibody discovery programs, JADE-002 and JADE-003. The company was founded upon assets licensed from Paragon Therapeutics.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

Tembo is a developer of a scalable and secure platform that facilitates the building, deployment, and management of various data services and applications using Postgres databases. The company aims to make the extensive open-source Postgres ecosystem more accessible for common use cases, effectively productizing it. By doing so, Tembo reduces the reliance on specialized database management expertise, allowing clients to enhance the capabilities of their databases.

CASI Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company dedicated to developing and commercializing innovative therapeutics, particularly in the fields of hematology and oncology. The company focuses on addressing unmet medical needs by acquiring and launching products in China, the United States, and globally. CASI's product portfolio includes several therapeutics, such as EVOMELA, which is used as a conditioning treatment prior to autologous stem cell transplants for multiple myeloma patients, along with CID-103, CNCT19, MARQIBO, ZEVALIN, and ENMD-2076. The company's primary revenue driver is the sales of EVOMELA, as it executes its strategy to become a leading biopharmaceutical player by leveraging its expertise in regulatory and commercial operations within the China market.

Bright Peak Therapeutics is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company specializes in cytokine therapeutics that enable tissue and cell-specific targeting of cytokine payloads. This approach aims to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging innovative immuno-cytokines, Bright Peak seeks to provide more effective therapeutic options for complex medical conditions.

Lycia Therapeutics is a biotechnology firm focused on discovering and developing first-in-class therapies. The company utilizes its innovative lysosomal targeting chimeras (LYTACs) platform to create therapeutics that target and degrade extracellular and membrane-bound proteins associated with challenging diseases, including cancer and autoimmune disorders. By addressing these difficult-to-treat conditions, Lycia Therapeutics aims to provide medical practitioners with effective treatment options to improve patient outcomes.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Archetype AI is a group of designers and technologists they are pioneering revolutionary artificial intelligence and interaction technologies for the real world.

Mirador Therapeutics envisions precision medicine for immune-mediated inflammatory and fibrotic diseases.

Enliven Therapeutics is a clinical-stage precision oncology company based in Boulder, Colorado, focused on developing innovative small molecule therapies to enhance patient outcomes. Established in July 2019 by Sam Kintz, Joe Lyssikatos, and Anish Patel, the company employs a unique discovery process that leverages clinically validated biological targets alongside advanced chemistry. This methodology aims to overcome the limitations of current therapies by creating potentially first-in-class treatments that address critical challenges such as tolerability, combinability, resistance, and disease progression, particularly in cases involving brain metastases. Enliven's product pipeline includes ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and act against various HER2 variants.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing innovative therapies for serious medical conditions with significant unmet needs. The company's lead product candidate, AT-007, is in phase I/II clinical trials for the treatment of galactosemia, while AT-001 is undergoing phase II trials for diabetic cardiomyopathy and phase I trials for diabetic peripheral neuropathy. Additionally, AT-003 is in phase I trials for diabetic retinopathy. The company also has preclinical candidates, such as AT-104, aimed at treating orphan hematological oncology conditions. Founded in 2016, Applied Therapeutics leverages advancements in technology and regulatory processes to create drugs targeting well-established molecular mechanisms.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company offers several products, including ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for the treatment of post-surgical ocular pain and inflammation, as well as allergic conjunctivitis and dry eye diseases. Ocular Therapeutix is also developing OTX-TP, an insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant for similar indications, along with OTX-TKI, an intravitreal implant targeting wet age-related macular degeneration. In addition, the company has preclinical programs focused on various ocular conditions. Ocular Therapeutix collaborates with Regeneron Pharmaceuticals to integrate its hydrogel technology with Regeneron's VEGF-targeting compounds for retinal disease treatments. Founded in 2006, the company is headquartered in Bedford, Massachusetts.

enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Adverum Biotechnologies is a clinical-stage gene therapy company focused on developing innovative treatments for ocular and rare diseases. Headquartered in Redwood City, California, the company aims to establish gene therapy as a new standard of care, aspiring to provide functional cures that restore vision and prevent blindness. Its pipeline includes several product candidates, notably ADVM-022, which targets wet age-related macular degeneration through a single intravitreal injection designed to deliver long-term therapeutic effects. Other candidates include ADVM-043 for alpha-1 antitrypsin deficiency and ADVM-053 for hereditary angioedema. Adverum collaborates with partners like Editas Medicine and Regeneron Pharmaceuticals to leverage advanced AAV vectors and develop treatments for various inherited retinal diseases and ocular therapeutic targets. Founded in 2006, the company was previously known as Avalanche Biotechnologies and rebranded in 2016.

Accompany Health is a health technology platform that delivers comprehensive in-home care to patients, particularly in underserved regions. The company focuses on providing primary care services, including chronic illness management and treatment of new symptoms. It aims to support low-income patients with complex health needs throughout their care journeys, offering both at-home and virtual services. By fostering long-term relationships with patients, Accompany Health ensures that individuals receive continuous support, with access to care available at all hours. This approach eliminates the need for waiting rooms and enhances the overall patient experience by emphasizing dignity and accessibility in healthcare.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.

SmithRx is a San Francisco-based company that designs and manages customized pharmacy benefit plans for employers, aiming to enhance employee guidance and satisfaction. Founded in 2016, SmithRx operates on a modern technology platform that emphasizes transparency, efficiency, and data analytics. The company provides a cost-competitive pharmacy benefit management (PBM) model, featuring a pass-through pricing structure, a unified technology system, and high-quality service assurances. Its in-house team combines expertise from various healthcare and technology sectors, including experience from notable companies, to deliver exceptional support and clinical programs. SmithRx focuses on empowering its clients with maximum flexibility and control over their pharmacy benefits, ultimately helping to reduce drug spending and improve the management of prescription benefits. The company's name reflects its commitment to precision and craftsmanship in the pharmacy benefits industry.

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Zero Networks Inc., founded in 2019 and based in Tel Aviv, Israel, specializes in cloud-based network security software. The company focuses on automating the development and enforcement of network access rules, allowing organizations to customize access for users and machines based on their communication patterns. Its technology eliminates the need for agents or manual policy configurations, providing a streamlined security solution. Additionally, Zero Networks includes a two-factor authentication mechanism that allows for secure connectivity even in unusual situations, ensuring that legitimate connections remain unaffected. By automating network access policies, Zero Networks aims to enhance security and prevent breaches, thereby safeguarding organizational operations.

Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies aimed at transforming the treatment landscape for inflammatory bowel disease (IBD). This chronic condition, which encompasses disorders such as ulcerative colitis and Crohn's disease, involves inflammation in the gastrointestinal tract. Spyre Therapeutics combines advanced antibody engineering with rational therapeutic combinations and precision medicine strategies to enhance patient selection. The company's goal is to create next-generation products that improve upon existing treatment options, which include anti-inflammatory drugs, immunosuppressants, and biologics. Through its robust pipeline, Spyre Therapeutics seeks to address the unmet needs of patients suffering from IBD.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

MBrace Therapeutics is a privately held biopharmaceutical company focused on enhancing the quality of life for cancer patients through the development of antibody-drug conjugates (ADCs). The company specializes in creating anti-tumor monoclonal human recombinant antibodies that target specific cancer cells. By utilizing advanced technology, MBrace Therapeutics aims to deliver potent toxic drugs directly into cancer cells, allowing for more precise treatment options. This innovative approach is designed to improve therapeutic outcomes and provide healthcare professionals with better tools to combat cancer.

Scope3 operates a supply chain emissions data platform that provides accurate and comprehensive emissions data to assist companies in integrating sustainability into their business decisions. The company develops models that outline the core inputs and outputs for products and services within the supply chain, enabling organizations to design more sustainable systems. Additionally, Scope3 prepares monthly sustainability reports that offer updated emissions data, allowing businesses to swiftly adapt to external changes and recognize their efforts in reducing carbon footprints.

MOMENT is a private markets liquidity provider that operates a fixed-income infrastructure tailored for contemporary financial firms. The company aims to enhance the accessibility and fairness of fixed-income markets by delivering innovative solutions to global fintech companies, traditional brokerages, and registered investment advisors. MOMENT develops an institutional-grade platform that facilitates stable income generation through advanced technology. By offering application programming interfaces (APIs), it empowers various firms managing substantial assets to engage in fixed-income investing, thereby modernizing the financial market landscape.

Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, established in 2019, focused on developing adeno-associated virus (AAV)-based gene therapies for monogenic diseases affecting the central nervous system (CNS). The company’s product pipeline includes several therapies currently in development, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha Gene Therapies aims to translate innovative treatments from research to clinical practice efficiently, leveraging a strategic partnership with The University of Texas Southwestern Medical Center to enhance its development and commercialization capabilities. The company's mission is to create curative medicines that target both rare and prevalent CNS conditions, thereby addressing severe and life-threatening diseases.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs.

SQLite Cloud is a cloud-based service that offers an easy-to-use and highly scalable platform for managing SQLite databases in the cloud. Our product provides a secure and reliable way to store, manage, and share SQLite databases without requiring any server setup or maintenance. With our service, customers can easily create new databases, import existing databases, and collaborate with others on their projects. Our product also offers various features such as automated backups, point-in-time recovery, and real-time replication, which ensures high availability and data durability. Our goal is to make database management as easy and hassle-free as possible for our customers.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatments. Founded in 2014 and based in South San Francisco, the company’s lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which is associated with resistance to various cancer therapies in solid tumors. Its second candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, targeting a critical component of the adenosine pathway linked to resistance against chemotherapy and immunotherapy. In addition to these products, ORIC is advancing multiple precision medicines aimed at addressing other mechanisms of cancer resistance. The company’s founders, Charles Sawyers and Scott Lowe, have extensive experience in identifying novel cancer targets that have led to innovative therapies.

Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.

NeoPhotonics is a technology company specializing in the development, manufacture, and sale of optical components and subsystems used in high-speed digital communications networks. The company offers a comprehensive range of active and passive optical products tailored for various market segments, including fiber-to-the-home (FTTH), data communications, storage area networks, and both metro and long-haul networks. Its product lineup includes transceivers, integrated splitters, multiplexers, and advanced optical modules, all designed to support a wide array of data rates and applications. Notably, NeoPhotonics is recognized for its innovative silica Planar Lightwave Circuit (PLC) technology, which plays a crucial role in modern optical networks. Additionally, the company produces MEMS-based Variable Optical Attenuators and Dynamic Channel Equalizers, enhancing the performance and efficiency of communication systems.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.

Carmot Therapeutics, Inc. is a clinical-stage biotechnology company based in Berkeley, California, with an additional office in San Francisco. Founded in 2008, the company focuses on discovering and developing therapies for metabolic diseases, including obesity and diabetes. Carmot employs a proprietary drug discovery approach known as Chemotype Evolution, which enables the exploration of novel chemical and biological frontiers. The company is advancing a portfolio of clinical-stage drug candidates, including CT-388, a once-weekly injectable dual GLP-1/GIP receptor agonist; CT-996, a once-daily oral GLP-1 receptor agonist; and CT-868, a once-daily injectable dual GLP-1/GIP receptor agonist for treating type 1 diabetes in patients with overweight or obesity. These innovative therapies aim to enhance glucose clearance and promote weight loss, addressing the fundamental causes of metabolic diseases.

Vocera Communications, Inc. specializes in providing secure and integrated communication and workflow solutions tailored for mobile workers across various sectors, including healthcare, hospitality, retail, energy, and education. The company’s offerings enhance communication and operational efficiency by integrating with existing clinical systems, such as electronic health records and nurse call systems. Vocera's product suite includes the Vocera Communication and Workflow System, which connects various communication devices, including hands-free and voice-controlled options, and the Vocera Care Experience software, designed to improve patient care quality and streamline manual tasks. Additionally, Vocera operates the Experience Innovation Network, collaborating with healthcare organizations to develop innovative solutions that improve patient and care team experiences. The company, founded in 2000 and headquartered in San Jose, California, serves approximately 1,700 healthcare facilities globally, including hospitals and clinics, and distributes its products through direct sales, resellers, and distributors.

Airspeed is a team-building platform designed for modern companies to foster digital connections among employees. The platform offers a range of applications that provide engaging solutions for celebrating employee milestones, recognizing colleagues, and facilitating connections within hybrid or remote teams. By serving as a system of record for organizational culture, Airspeed helps businesses enhance employee engagement, retention, and productivity, ultimately contributing to a strong and collaborative company culture.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing innovative therapies for serious medical conditions with significant unmet needs. The company's lead product candidate, AT-007, is in phase I/II clinical trials for the treatment of galactosemia, while AT-001 is undergoing phase II trials for diabetic cardiomyopathy and phase I trials for diabetic peripheral neuropathy. Additionally, AT-003 is in phase I trials for diabetic retinopathy. The company also has preclinical candidates, such as AT-104, aimed at treating orphan hematological oncology conditions. Founded in 2016, Applied Therapeutics leverages advancements in technology and regulatory processes to create drugs targeting well-established molecular mechanisms.

Tembo is a developer of a scalable and secure platform that facilitates the building, deployment, and management of various data services and applications using Postgres databases. The company aims to make the extensive open-source Postgres ecosystem more accessible for common use cases, effectively productizing it. By doing so, Tembo reduces the reliance on specialized database management expertise, allowing clients to enhance the capabilities of their databases.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Apogee Therapeutics is a biotechnology company based in San Francisco, California, founded in 2022. The company focuses on developing differentiated biologics for the treatment of immunological and inflammatory disorders, specifically targeting atopic dermatitis and chronic obstructive pulmonary disease. Apogee Therapeutics aims to address high unmet medical needs by advancing novel therapies that utilize advanced antibody engineering to enhance therapeutic properties such as half-life. The company's key programs, APG777 and APG808, are designed to leverage established mechanisms of action to improve treatment outcomes for patients suffering from these conditions.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns is dedicated to advancing a pipeline of innovative therapeutic candidates. Its notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, an amine oxidase inhibitor. The company leverages its expertise in disease biology and medicinal chemistry, along with a capital-efficient drug discovery model and robust clinical development capabilities, to address significant unmet medical needs in both China and the global market.

Nightfall is a cloud data protection platform that utilizes machine learning to identify and manage business-critical data across various applications. It integrates seamlessly with all SaaS, APIs, and data infrastructures, automatically classifying sensitive information to ensure comprehensive data protection. The platform addresses data exposure and hygiene issues without impacting end users by setting up automated workflows for quarantines, deletions, and alerts. Additionally, Nightfall offers a Developer Platform that provides flexible APIs and SDKs, allowing developers to incorporate its data classification and protection capabilities into their applications. This approach not only enhances security but also saves time for users, helping organizations maintain the safety of their business data.

Dgraph Labs, Inc. is a technology company based in San Francisco, California, that specializes in developing and operating a graph database. Founded in 2016, Dgraph offers a low-latency solution designed for efficient retrieval of structured data, catering to both small startups and large enterprises. Its flagship product, Slash Enterprise, is a fully-managed and serverless solution that supports terabytes of data and operates on dedicated, multi-zone clusters across major cloud platforms such as AWS, Azure, and GCP. The company's graph database is particularly suited for real-time user queries and addresses various use cases, including semantic search, pattern matching, and fraud detection, enabling clients to effectively manage, represent, and visualize large datasets.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from classical complement-mediated disorders affecting the body, brain, and eye. The company's research is centered around its platform technology that targets classical complement-mediated autoimmune and neurodegenerative diseases associated with the abnormal activation of C1q, a key molecule in the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody intended for intravenous use in treating autoimmune and neurodegenerative disorders. Another candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration aimed at neurodegenerative ophthalmic conditions. The company employs a disciplined, biomarker-driven development strategy to ensure its therapies effectively engage the target at tolerable doses within the intended patient tissues, while also exploring additional indications within both orphan and larger market segments.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.

Meltano is an open-source DataOps platform that integrates various leading open-source tools for managing the data lifecycle. It incorporates the Singer standard for data integration, featuring a library of over 200 connectors, as well as tools like dbt for data transformation, Airflow for orchestration, and plans to include Superset for data visualization. Meltano aims to simplify the processes of configuration, deployment, and monitoring while allowing data teams to adopt practices such as version control and continuous integration/continuous deployment. The platform collaborates with a community of over 1,200 professionals from startups, global enterprises, and consultancies to advance data infrastructure. Thousands of active projects utilizing Meltano are presently in operation across various organizations, demonstrating its practical application and adaptability in the data management landscape.

MOMENT is a private markets liquidity provider that operates a fixed-income infrastructure tailored for contemporary financial firms. The company aims to enhance the accessibility and fairness of fixed-income markets by delivering innovative solutions to global fintech companies, traditional brokerages, and registered investment advisors. MOMENT develops an institutional-grade platform that facilitates stable income generation through advanced technology. By offering application programming interfaces (APIs), it empowers various firms managing substantial assets to engage in fixed-income investing, thereby modernizing the financial market landscape.

Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focused on advancing cancer treatment through innovative diagnostics. The company's CELsignia diagnostic platform utilizes living tumor cells to uncover specific cellular processes that drive cancer in individual patients. This approach enables the identification of new cancer sub-types that traditional molecular diagnostics may overlook, ultimately expanding therapeutic options. Celcuity is developing the CELsignia HSF test to diagnose two new sub-types of HER2-negative breast cancer and the CELsignia MP test for diagnosing 11 sub-types across various cancers, including breast, lung, colon, ovarian, kidney, and bladder. The company is also advancing its lead therapeutic candidate, gedatolisib, a pan-PI3K and mTOR inhibitor, currently being evaluated in a Phase 3 clinical trial for patients with advanced HR+/HER2- breast cancer.

The Public Health Company is focused on creating a global biosecurity platform that offers a Software as a Service (SaaS) solution for managing bio-risks within enterprises. Founded in 2020 and headquartered in Palo Alto, California, the company combines expert knowledge with advanced technology to provide a comprehensive approach to enterprise risk management. Its platform addresses various physical world threats, delivering actionable and predictive intelligence that enables dynamic risk management with exceptional speed and scale. The Public Health Company serves businesses, healthcare providers, and public health systems, positioning itself as a key player in enhancing public health and safety through innovative solutions.

Kelonia Therapeutics is developing a new wave of genetic medicines using its next-generation vivo gene delivery platform. The company's cutting-edge in vivo gene delivery technology is simple and elegant, relying on a few potent lentiviral vector-like particles to precisely and efficiently deliver genetic cargo to the desired target tissue, and only that tissue, every time. To deliver genetic cargo only to the desired tissue, the lentiviral vector gene delivery platform employs a simple and elegant solution based on decades of research, development, and technical experience. Kelonia's mission is to develop a new wave of accessible genetic medicines that will transform the lives of patients suffering from a broad range of conditions.

Vanilla is an innovative Estate Advisory Platform designed to enhance the estate planning experience for wealth management firms and their clients. By providing a comprehensive suite of tools, Vanilla enables advisors, planners, and estate attorneys to offer tailored advice, strengthen client relationships, and attract new business. The platform addresses inefficiencies in document preparation and enhances understanding of estate complexities, making it easier for clients to navigate estate-related challenges after a death. Ultimately, Vanilla aims to simplify and scale estate analysis, allowing estate professionals to deliver more value and support to their clients in managing estate tax considerations and planning effectively.

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Quiq, Inc. is a technology company based in Bozeman, Montana, founded in 2015. It specializes in developing customer service messaging management software that enhances communication between businesses and their customers. Quiq offers a cloud-based platform that allows consumers to interact with brands through various digital messaging channels, including SMS, web chat, and social messaging apps. The company's flagship product, Quiq IQ, enables the creation and deployment of AI-driven bots to assist customer service agents in managing inquiries efficiently. Quiq's solutions are designed to provide personalized and proactive customer support at scale, facilitating seamless transitions from AI to human agents. With a focus on customer experience and advanced automation capabilities, Quiq serves notable clients such as Volvo and IHG Hotels & Resorts, helping them implement effective AI strategies to improve customer engagement. In March 2017, the company rebranded from Centricient Inc. to its current name, Quiq, reflecting its commitment to innovative customer interaction solutions.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Ocelot Bio brings new treatment options to patients with severe liver disease. It researches and discovers medicines that help in the treatment of hepatorenal syndrome, a complication of severe liver disease.

Astronomer, Inc. is a company based in Cincinnati, Ohio, that specializes in developing a managed platform for data orchestration, primarily utilizing Apache Airflow. Established in 2014, Astronomer offers a comprehensive suite of products and services through its platform, known as Astro. This platform is designed to streamline the process of building, running, and monitoring data pipelines-as-code, catering to the needs of data engineers, scientists, and analysts. By providing tools for deploying, managing, and scaling data workflows, Astronomer enhances the availability of trusted data for organizations, making it easier for data teams to conduct business analytics effectively. As a commercial developer of Airflow, Astronomer plays a significant role in the data orchestration landscape, serving hundreds of thousands of teams globally.

SmithRx is a San Francisco-based company that designs and manages customized pharmacy benefit plans for employers, aiming to enhance employee guidance and satisfaction. Founded in 2016, SmithRx operates on a modern technology platform that emphasizes transparency, efficiency, and data analytics. The company provides a cost-competitive pharmacy benefit management (PBM) model, featuring a pass-through pricing structure, a unified technology system, and high-quality service assurances. Its in-house team combines expertise from various healthcare and technology sectors, including experience from notable companies, to deliver exceptional support and clinical programs. SmithRx focuses on empowering its clients with maximum flexibility and control over their pharmacy benefits, ultimately helping to reduce drug spending and improve the management of prescription benefits. The company's name reflects its commitment to precision and craftsmanship in the pharmacy benefits industry.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Astrix Security specializes in protecting non-human identities such as API keys, service accounts, and access tokens, addressing a critical aspect of identity security for organizations. The company's cloud-based platform provides comprehensive visibility into these identities, enabling the automatic identification and mitigation of excessive or harmful access that can lead to supply chain threats and data breaches. By controlling the lifecycle of non-human identities, Astrix offers an agentless solution that enhances risk assessment and facilitates automated remediation. This allows organizations to safely harness the benefits of app-to-app integration and automation while minimizing the risk of service supply chain attacks.

Zero Networks Inc., founded in 2019 and based in Tel Aviv, Israel, specializes in cloud-based network security software. The company focuses on automating the development and enforcement of network access rules, allowing organizations to customize access for users and machines based on their communication patterns. Its technology eliminates the need for agents or manual policy configurations, providing a streamlined security solution. Additionally, Zero Networks includes a two-factor authentication mechanism that allows for secure connectivity even in unusual situations, ensuring that legitimate connections remain unaffected. By automating network access policies, Zero Networks aims to enhance security and prevent breaches, thereby safeguarding organizational operations.

Decodable is a data integration and engineering platform focused on serverless streaming data, founded in 2021 and based in San Francisco, California. The company provides software that enables applications and data engineers to construct complex data pipelines efficiently. Its platform facilitates quick connections to various messaging, storage, and database systems, allowing users to collect, process, and deliver data effectively to both offline and online systems.

3Box Inc. is a New York-based company founded in 2018 that provides innovative solutions for decentralized identity and open data management. Its primary offerings include 3box.io, a social profiles application designed for Ethereum users and communities, and 3box.js, an API that facilitates user onboarding and data management for web3 developers. Additionally, the company provides 3box-dapp, which enables users to create and manage their social profiles, sign in to decentralized applications (dApps), interact with other users, build a reputation, and securely store data. The 3Box platform prioritizes simplicity, security, and privacy, allowing applications that utilize its services to be more trustworthy and reduce data management liabilities.

Running Tide is a global ocean health company focused on developing innovative aquaculture techniques to enhance both flavor and nutritional value while addressing climate challenges. By leveraging scientific expertise, the company aims to produce sustainable, low-carbon protein sources. Running Tide employs nature-based interventions to remove carbon from the atmosphere and combat ocean acidification. Its approach involves the design and development of integrated software and hardware systems that utilize photosynthesis, ocean currents, and gravity to sequester carbon in the deep ocean. Through the analysis of ocean data, Running Tide seeks to optimize the use of the Earth's vast marine environments, thereby improving ocean health and amplifying the natural restorative capabilities of the ocean.

Atom Computing Inc. is a company based in Berkeley, California, that focuses on manufacturing scalable quantum computers utilizing individual atoms. Founded in 2018, the company harnesses the quantum mechanical properties of atoms to process information and address complex problems that traditional computers cannot solve. Atom Computing's technology allows for the optical control, scaling, and stabilization of these atoms, facilitating efficient quantum calculations in various fields, including drug design, computational chemistry, and general computing. Through its innovative approach, Atom Computing aims to advance the development of quantum technology and expand its applications across multiple industries.

Apogee Therapeutics is a biotechnology company based in San Francisco, California, founded in 2022. The company focuses on developing differentiated biologics for the treatment of immunological and inflammatory disorders, specifically targeting atopic dermatitis and chronic obstructive pulmonary disease. Apogee Therapeutics aims to address high unmet medical needs by advancing novel therapies that utilize advanced antibody engineering to enhance therapeutic properties such as half-life. The company's key programs, APG777 and APG808, are designed to leverage established mechanisms of action to improve treatment outcomes for patients suffering from these conditions.

Mythic Therapeutics is a biotechnology company dedicated to advancing cancer treatment through innovative antibody-drug conjugates (ADCs). The company specializes in a protein engineering approach that enhances the potency of ADCs while maintaining safety, allowing for more effective targeted therapies across various tumor types. By improving the uptake of these therapeutics in cancerous cells and minimizing payload release in healthy cells, Mythic Therapeutics aims to increase the efficacy of treatments without causing significant side effects or toxicity. This technology positions the company to make a meaningful impact in cancer care, enabling healthcare practitioners to better utilize ADCs for a wide array of patients.

Suki is a technology company focused on enhancing healthcare documentation through AI-driven voice solutions. Its flagship product, Suki Assistant, allows physicians to complete administrative tasks more efficiently, significantly reducing the time spent on documentation. The company also offers a proprietary voice platform that leverages advanced natural language processing and machine learning technologies, ensuring high accuracy and a seamless user experience. By providing these innovative voice tools, Suki aims to alleviate the administrative burden on clinicians, ultimately transforming the healthcare technology landscape into a more assistive and integrated system.

Ablaze Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted radiotherapy (TRT) treatments for cancer patients. The company aims to introduce innovative TRT products to the Chinese market, leveraging the founders' extensive experience and networks in cross-border product development and deal-making. By focusing on advanced therapeutic solutions, Ablaze Pharmaceuticals seeks to improve the outcomes and quality of life for cancer patients in China.